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Theroleofallogeneic (allo-) andautologousstemcell transplantation (auto-SCT) in themanagementofpatientswith
transformed indolent nonfollicular non-Hodgkin lymphoma is unknown. This is amulticenter, retrospective cohort
study of patients with biopsy-proven indolent B cell nonfollicular non-Hodgkin lymphoma and simultaneous or
subsequent biopsy-proven aggressive histology transformation who were treated with allo-SCT or auto-SCT be-
tween 1996 and 2013. All patients receivedmyeloablative conditioning regimens. Outcomeswere comparedwith a
cohort of 246 patients with transformed follicular lymphoma who also underwent allo-SCT (n ¼ 47) or auto-SCT
(n¼ 199) across the same institutions and time frame. Thirty-four patients were identiﬁed with the following un-
derlying indolent histologies: 15 (44%) marginal zone lymphoma, 11 (32%) chronic lymphocytic leukemia, 6 (18%)
small lymphocytic lymphoma, and2 (6%) lymphoplasmacytic lymphoma. Patients receivedvarious anthracyclineor
platinum-containing chemotherapy regimens for transformation, incorporating rituximab in25 (74%). Twelve (35%)
subsequently underwent allo-SCT, whereas 33 (65%) underwent auto-SCT. The 3-year overall survival rate after
transplantationwas 67% (allo-SCT 54%, auto-SCT 74%), and 3-year progression-free survival rate was 49% (allo-SCT
40%, auto-SCT 54%). The 3-year nonrelapse mortality rate was 14% (allo-SCT 15%, auto-SCT 7%). Transplant-related
mortality at 100 days was 17% for allo-SCT and 0% for auto-SCT. Adjusted for type of stem cell transplantation, 3-
year overall survival, progression-free survival, and nonrelapse mortality rates were similar to those of patients
with transformed follicular lymphoma receiving allo-SCT and auto-SCT (P ¼ .38, P¼ .69, and P¼ .54, respectively).
Allo-SCTand auto-SCTmay be reasonable treatments for selected patientswith transformed nonfollicular indolent
lymphoma, although medium-term outcomes and toxicity appear to be more favorable with auto-SCT.
 2014 American Society for Blood and Marrow Transplantation.edgments on page 1817.
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Patients with indolent non-Hodgkin lymphomas may
experience disease transformation to aggressive histology
Table 1
Patient Characteristics at Time of Diagnosis of Indolent Lymphoma and
Transformation
Characteristics Allo-SCT
(n ¼ 12)
Auto-SCT
(n ¼ 22)
P
n % n %
At diagnosis of indolent lymphoma
Country
Canada 10 84 15 68 .30
Australia 2 17 7 32
Male gender 4 33 10 46 .72
Age at diagnosis, yr
Median 48 53 .29
Range 24-64 32-64
Indolent histology at original
diagnosis
.05
Marginal zone lymphoma 3 25 12 55
Chronic lymphocytic leukemia 6 50 5 23
Lymphoplasmacytic lymphoma 2 17 0 0
Small lymphocytic lymphoma 1 8 5 23
Systemic regimens for iNHL .90
0 3 25 4 18
1 6 50 12 55
2-3 3 25 6 27
Pretransformation radiotherapy 1 8 5 23 .39
At diagnosis of transformation
Year of transformation 1.0
1996-2005 7 58 12 55
2006-2013 5 42 10 45
Years from iNHL to transformation .12
Median 2.1 2.9
Range .6-7.7 .4-18.3
Transformation histology .35
Diffuse large B cell lymphoma 11 92 22 100
Burkitt-like lymphoma 1 8 0 0
Advanced stage 12 100 19 86 .54
Elevated LDH* 3/7 43 12/19 63 .41
Systemic regimens for
transformation
.85
1 8 67 14 64
2 3 25 7 32
3 1 8 1 4
Last line of chemotherapy .08
CHOP 7 58 5 27
Platinum-containing 3 25 14 64
Othery 2 17 3 14
Last chemotherapy with rituximab 7 58 18 82 .22
iNHL indicates indolent non-Hodgkin lymphoma; LDH, lactate dehydroge-
nase; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone.
* Number of patients/number of patients with available data.
y Other regimens such as carmustine, etoposide, cytarabine, melphalan
(mini-BEAM) and cyclophosphamide, vincristine, doxorubicin, dexametha-
sone, cytarabine, methotrexate (hyper-CVAD).
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approximately 2% to 3% per year in patients with follicular
lymphoma (FL) [1-4]. The incidence and clinical course of
patients with other nonfollicular indolent histologies expe-
riencing transformation appear to be similar based on
limited data [5-8].
Several studies suggest that certain patients with trans-
formed indolent lymphomas may beneﬁt from allogeneic
(allo-) or autologous stem cell transplantation (auto-SCT).
However, these studies have included only patients with
transformed FL [9-16] or a minority of patients with other
indolent histologies [17-25]. No large studies have evaluated
SCT strategies exclusively in patients with transformed non-
FL, with the exception of Richter’s transformation in chronic
lymphocytic leukemia [26-28]. Therefore, the purpose of this
study was to evaluate outcomes after allo-SCT or auto-SCT in
patients with transformed non-FL and to compare themwith
a similar population of patients with transformed FL under-
going the same treatments.
METHODS
Patient Identiﬁcation
This is an international, multicenter cohort study of patients with
transformed non-FL who were treated with allo-SCT or auto-SCT during
1996 to 2013. Canada has no centralized transplant data repository, and
therefore all transplant centers in the Canadian Blood and Marrow Trans-
plant Group were contacted. These transplant centers reported all cases
with transformed indolent lymphoma treated with SCT, which were com-
bined into a database of 391 patients. Results for the subgroup of patients
with transformed FL were previously published [14] but not for those with
transformed nonfollicular indolent histologies. In Australia, there is a
voluntary but complete registration and reporting process to a national stem
cell transplantation registry. However, for this study, data for all eligible
similar transplant cases treated only at Peter MacCallum Cancer Centre,
Melbourne, Australia, were collected from the institutional database.
Adult patients with biopsy-proven indolent non-Hodgkin lymphoma
and subsequent biopsy-proven aggressive histology B cell lymphoma
transformation treated with allo-SCT or auto-SCT were included. Patients
who initially presented with simultaneous indolent and aggressive histol-
ogies (discordant or composite) were excluded. Patients transplanted for a
subsequent diagnosis of Hodgkin lymphoma or T cell lymphoma and those
with a clinical diagnosis of transformation without biopsy conﬁrmation
were excluded. Patients with an initial diagnosis of aggressive lymphoma
with a subsequent indolent histology relapse were also excluded. Pathology
was reviewed at each academic center for transformed lymphoma cases
before SCT.
Disease and Treatment Data
Standard staging investigations, including computed tomography scans
and bone marrow biopsies, were completed at the time of diagnosis and
transformation. 18-F deoxyglucose positron emission tomography scans
were not routinely performed. Advanced stage at transformation was
deﬁned as Ann Arbor stage III or IV or stage I or II with B symptoms or bulky
disease (10 cm).
At the time of transformation, patients received at least 1 cycle of
combination chemotherapy, most commonly anthracycline or platinum-
containing, with or without rituximab. Response to chemotherapy was
retrospectively interpreted by participating physicians according to the
1999 International Working Group criteria [29]. Patients underwent allo-
SCT or auto-SCT for any episode of transformation (ﬁrst or subsequent
relapse) and were selected for SCT primarily on the basis of chemo-
sensitivity. Similar criteria were applied for response evaluation after allo-
SCT or auto-SCT. The choice of chemotherapy regimens, SCT type, stem
cell source and mobilization procedures, graft-versus-host disease prophy-
laxis, and supportive care followed individual institutional standards.
Statistical Analysis
Overall survival (OS), calculated from the date of allo-SCT or auto-SCT to
the date of last follow-up or death from any cause, was the primary
endpoint. Progression-free survival (PFS), calculated from the date of allo-
SCT or auto-SCT to the date of last follow-up (censored observations) or
subsequent progression, relapse, or death from any cause (events), was a
secondary endpoint. Nonrelapse mortality (NRM) was calculated from the
date of allo-SCT or auto-SCT to the date of last follow-up (censoredobservations) or death from any cause before lymphoma relapse or pro-
gression (events). Death within 100 days of transplant was considered as
transplant-related mortality.
Outcomes were also compared with a cohort of 246 patients with
transformed FL treated with either allo-SCT (n ¼ 47) or auto-SCT (n ¼ 199)
across the same institutions, countries, and time period, identiﬁed within
the databases described above. Patient characteristics at diagnosis, trans-
formation, and transplantation were compared between groups using
Fisher’s exact test for discrete variables and Student’s t-test for continuous
variables. Three-year OS, PFS, and NRM rates were estimated using the
Kaplan-Meier method and compared using the log-rank test [30]. Data were
analyzed using SPSS version 14.0 for Windows (SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
Patient and treatment characteristics are described in
Tables 1 and 2. Thirty-four patients (25 Canada, 9 Australia)
were identiﬁed with the following underlying indolent
histologies: 15 (44%) marginal zone lymphoma, 11 (32%)
chronic lymphocytic leukemia, 6 (18%) small lymphocytic
Table 2
Patient Characteristics at Time of Stem Cell Transplantation
Characteristics Allo-SCT
(n ¼ 12)
Auto-SCT
(n ¼ 22)
P
n % n %
Year of transplantation .29
1996-2005 7 58 8 36
2006-2013 5 42 14 64
Age at SCT, yr .11
Median 55 58
Range 26-67 43-66
Months from transformation to SCT .13
Median 6 6
Range 2-19 2-86
Chemosensitivity pre-SCT .04
Complete response 1 8 11 50
Partial response 9 77 11 50
Stable disease 1 8 0 0
Progressive disease 1 8 0 0
Stem cell source
Peripheral blood 4 33 22 100 <.001
Bone marrow 8 67 0 0
High-dose (conditioning) regimen <.001
Chemotherapy þ total body
irradiation
6 50 1 4
Chemotherapy only 6 50 21 96
Allogeneic donor type Not applicable
Matched sibling 3 25
Mismatched related donor 4 33
Matched unrelated donor 5 42
Graft-versus-host disease Not applicable
Acute 5 42
Chronic 5/11* 45
Prophylaxis
Cyclosporine þ methotrexate 11 92
Cyclosporine þ mycophenolate 1 8
Antithymocyte infusion 4 33
Response to SCT
.06Complete response 6 50 19 86
Partial response 3 25 3 14
Stable disease 0 0 0 0
Progressive disease 1 8 0 0
Not assessed* 2 17 0 0
Transplant-related mortality
at 100 d
2 17 0 0
.12
* Two allo-SCT patients experienced transplant-related mortality before
response assessment.
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tient and disease characteristics were generally similar be-
tween both transplant groups, both at the time of diagnosis
of indolent and at the time of transformation.
Most transformation events occurred in patients who had
received 1 to 2 lines of systemic therapy for their indolent
lymphoma. Themedian time from initial diagnosis of indolent
lymphoma to transformation was 2.5 years, with a wide time
range (.4 to 18 years). At transformation, approximately half of
the patients had an elevated serum level of lactate dehydro-
genase and almost all had advanced stage disease. Patients
received various anthracycline or platinum-containing
chemotherapy regimens for transformation, incorporating
rituximab in 25 patients (74%), with no signiﬁcant difference
in frequency between allo-SCT and auto-SCT (P ¼ .22).
Transplantation Characteristics
Twelve patients (35%) were treated with allo-SCT and 22
(65%) with auto-SCT. None of the patients in the allo-SCT
group underwent prior auto-SCT for relapsed indolent lym-
phoma. Twenty-two (65%) received SCT as part of their
upfront therapy (immediately after 1 line of chemotherapy
for transformed disease), whereas the other 12 (35%)received it in the relapsed setting (after 2 to 3 lines of
chemotherapy for transformed disease).
Most patients were transplanted with chemosensitive
disease (83% allo-SCT, 100% auto-SCT). Compared with allo-
SCT patients, those treated with auto-SCT were more likely
to be transplanted in a slightly more recent era and at an
older age, using peripheral blood stem cells, and after a high-
dose therapy regimen that did not include total body
irradiation. All patients undergoing allo-SCT received mye-
loablative conditioning. For the 12 allo-SCT patients, donors
were 3 matched siblings, 5 matched unrelated, and 4 mis-
matched related. Transplant-related mortality at 100 days
was 17% and 0% for allo-SCT and auto-SCT, respectively
(P ¼ .12).
Outcomes
With a median follow-up of 3.7 years (range, .4 to
10.7 years) in surviving patients, the 3-year OS rate after SCT
for the entire cohort was 67% (standard error [SE], 9%), with
no statistical difference between patients treated with allo-
SCT (54%; SE, 15%) or auto-SCT (74%; SE, 10%), P ¼ .16, as
shown in Figure 1. The 3-year PFS rate after SCT for the entire
cohort was 49% (SE, 9%), again with no statistical difference
between patients treated with allo-SCT (40%; SE, 15%) or
auto-SCT (54%; SE, 11%), P ¼ .13, as shown in Figure 2. The 3-
year NRM rate after SCT for the entire cohort was 14% (SE,
7%), which was signiﬁcantly greater in patients treated with
allo-SCT (15%; SE, 15%) compared with auto-SCT (7%; SE, 6%;
P ¼ .02; Figure 3).
Outcomes were then compared with a cohort of 246 pa-
tients with transformed FL treated with allo-SCT (n ¼ 47) or
auto-SCT (n ¼ 199). Patient, disease, and treatment charac-
teristics were similar between patients with transformed FL
and non-FL, with the exception of a signiﬁcantly higher
proportion of males in the former group (Supplemental
Tables 1 and 2). Adjusted for type of SCT only, the 3-year
OS rate after allo-SCT was statistically similar for patients
with non-FL (47%; SE, 8%) and FL (54%; SE, 15%). Corre-
spondingly, the 3-year OS rate for non-FL transformed lym-
phoma after auto-SCT (74%; SE, 10%) was statistically similar
to that of patients with transformed FL (68%; SE, 3%), with
P ¼ .38 for all adjusted comparisons, as shown in
Supplemental Figure 1.
Adjusted for type of SCT only, the 3-year PFS rate after
allo-SCT (40%; SE, 15%) was statistically similar to that of
patients with transformed FL (46%; SE, 8%). Correspondingly,
the 3-year PFS rate after auto-SCT (54%; SE, 11%) was statis-
tically similar to that of patients with transformed FL (49%;
SE, 4%), with P¼ .69 for all adjusted comparisons, as shown in
Supplemental Figure 2. Adjusted for type of SCT only, the 3-
year NRM rate after allo-SCT (17%; SE, 11%) was statistically
similar to that of patients with transformed FL (36%; SE, 8%).
Correspondingly, the 3-year NRM rate after auto-SCT (7%;
6%) was statistically similar to that of patients with trans-
formed FL (6%; SE,2%), with P ¼ .54 for all adjusted compar-
isons, as shown in Supplemental Figure 3.
DISCUSSION
This report presents our multi-institutional, retrospective
analysis of the outcomes of transformed non-FL patients
treated with allo-SCT or auto-SCT. We observed that patients
with transformed non-FL treated with hematopoietic SCT
experience outcomes comparablewith those of patients with
transformed FL receiving similar treatments. This suggests
the biology of the aggressive component, rather than that of
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Our data therefore corroborate that allo-SCT and auto-SCT
may be appropriate treatments for patients with trans-
formed indolent lymphoma regardless of the underlying
histology.
Overall, our OS and PFS estimates are consistent with
other cohorts of various transformed indolent histologies in
the literature. Ban-Hoefen et al. [18] published a retrospec-
tive analysis of the National Comprehensive Cancer Network
database of 118 patients with transformed indolent lym-
phoma (14% non-FL), inwhich the 2-year OS rate was 65% for
patients undergoing allo-SCT (n ¼ 18) and 83% for those
receiving auto-SCT (n ¼ 50). Villa et al. [25] described a
single-institution cohort of 105 patients (4% non-FL) with
transformed indolent lymphoma in which the 3-year OS and
PFS rates were 54% and 42%, respectively, for the subgroup of
50 patients who proceeded with auto-SCT. In this cohort,
only 4 patients received allo-SCT [25]. Finally, in a subgroup
analysis of the National Cancer Institute of Canada LY-121211109876543210
Time since transplantation (years)
1.0
0.8
0.6
0.4
0.2
0.0
lavivruS
eerF-noissergor P
AUTO 3-yr PFS 54%
ALLO 3-yr PFS 40%
P = .13
Figure 2. Progression-free survival by transplant type (n ¼ 34). AUTO in-
dicates auto-SCT (green); ALLO, allo-SCT (blue).randomized trial of salvage chemotherapy and auto-SCT for
relapsed/refractory aggressive non-Hodgkin lymphomas, the
subset of 89 patients with transformed indolent lymphomas
experienced 4-year event-free survival rate after auto-SCT of
45% [21].
Studies of SCT for transformed indolent lymphomas have
not compared outcomes according to FL versus non-FL his-
tology, with the exception of a retrospective study of 27
patients with transformed indolent lymphoma that found no
differences in disease-free survival or OS between patients
with transformed chronic lymphocytic leukemia/small
lymphocytic lymphoma (n ¼ 6) or FL (n ¼ 21) treated with
auto-SCT (P ¼ .66) [20]. A few publications of auto-SCT and
allo-SCT for Richter’s transformation of chronic lymphocytic
leukemia/small lymphocytic lymphoma suggest that a sub-
group of patients may beneﬁt from such treatments [26-28].
However, our chronic lymphocytic leukemia/small lympho-
cytic lymphoma subgroup was not large enough to deter-
mine whether these patients beneﬁt from allo-SCT over
auto-SCT compared with other indolent histologies.
The main strength of the present analysis is that the study
base was assembled through a multi-institutional collabora-
tion, reﬂecting a broad pattern of practice. Additionally, results
were compared with a very large cohort of 246 patients with
transformed FL treated with allo-SCT or auto-SCT, in actuality
much larger than any other published in the literature.
Because FL is more common than the other individual B cell
lymphoid cancer subtypes, studies of transformed indolent
lymphoma have included none [9-16] to few [17-25] patients
with non-FL. Although the present study represents a
considerable experience of SCT in patients with transformed
non-FL, data collected on 34 patients transplanted over
17 years may not necessarily reﬂect the current state of
transplant outcome in similar patient populations.
Our study has several limitations. First, the patients re-
ported in our series were highly selected for allo-SCT or auto-
SCT based on multiple factors, including age, ﬁtness,
response to chemotherapy, and physician and patient choice.
Therefore, results may not be necessarily generalized to the
greater population of patients with transformed non-FL
potentially eligible for SCT. Second, given the retrospective,
nonrandomized design, comparisons between groups are
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lacks sufﬁcient statistical power to identify modest differ-
ences. Third, various indolent lymphomas, each with a
particular natural history and speciﬁc management, were
combined for analysis. Ideally, the management and out-
comes of each indolent subtype transformation should be
evaluated separately, but our small sample size did not
permit such analysis. Fourth, 18-F deoxyglucose positron
emission tomography was not routinely performed in pa-
tients included in this study. The lack of these data makes it
difﬁcult to determine how well balanced the allo-SCT and
auto-SCT groups were, especially in the view of the differ-
ence in chemosensitivity between both groups shown in
Table 2.
Additionally, all allo-SCT patients underwent myeloa-
blative conditioning, which likely contributed to the high
transplant-related mortality in this group. A recent report
from the Center for International Blood and Marrow Trans-
plant Research suggests that reduced-intensity conditioning
allo-SCT may maintain efﬁcacy while reducing toxicity in
patients with transformed FL [16]. Furthermore, the allo-SCT
group is heterogeneous, including recipients of stem cells
from matched related, matched unrelated, and mismatched
related donors. Given the study time period, current stan-
dards for HLA matching were not routinely performed for
most cases, limiting the ability to understand the outcomes
of allo-SCT in this series.
Finally, about 80% of the patients in our study received
rituximab-containing salvage chemotherapy before SCT.
Unfortunately data on prior rituximab use for indolent
lymphoma (before transformation) were not available.
Again, the sample size limited our ability to draw any con-
clusions about the impact of rituximab. Limited retrospective
data suggest that the addition of rituximab to chemotherapy
improves outcomes in patients with transformed indolent
lymphoma who proceed with auto-SCT, although the effect
in patients treated with allo-SCT is largely unknown
[18,25,31-33].
In summary, auto-SCT and allo-SCT may be reasonable
treatments for selected patients with transformed indolent
non-FL, although outcomes and toxicity appear to be more
favorable with auto-SCT. In the short to medium term (up to
5 years after allo-SCT or auto-SCT), there is no clear advan-
tage to any particular transplantation strategy, although
longer observation is required to clarify whether there truly
is a fraction of patients cured with either modality. Further
research is necessary to determine the optimal strategy,
including timing, drug sequencing, and combinations with
the most favorable beneﬁt-to-risk ratio.ACKNOWLEDGMENTS
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